Evidence map›Paper›PMID 40752248›Full record

ArticleVaccine2025

Facilitators and barriers to implementation of HPV vaccination in Tanzania: a mixed-methods study exploring perspectives from national, subnational, and community stakeholders, 2018-2023.

Julie Garon Carlton, Doreen Pamba, Nessa Ryan, Willyhelmina Olomi, Nyanda Elias Ntinginya, Florian Tinuga, Lucas Maganga, Wiston William, Anange Lwilla, Emmanuel Kapesa and 7 more

Abstract read
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Julie Garon CarltonU.S. Centers for Disease Control and Prevention, Global Health Center; Atlanta, GA, USA. Electronic address: jcarlton@cdc.gov.
Doreen PambaNational Institute for Medical Research, Mbeya, Tanzania.
Nessa RyanU.S. Centers for Disease Control and Prevention, Global Health Center; Atlanta, GA, USA.
Willyhelmina OlomiNational Institute for Medical Research, Mbeya, Tanzania.
Nyanda Elias NtinginyaNational Institute for Medical Research, Dar es Salaam, Tanzania.
Florian TinugaMinistry of Health, Dodoma, Tanzania.
Lucas MagangaNational Institute for Medical Research, Mbeya, Tanzania.
Wiston WilliamNational Institute for Medical Research, Mbeya, Tanzania.
Anange LwillaNational Institute for Medical Research, Mbeya, Tanzania.
Emmanuel KapesaNational Institute for Medical Research, Mbeya, Tanzania.
Joel MwakisisileNational Institute for Medical Research, Mbeya, Tanzania.
Daniel MagesaU.S. Centers for Disease Control and Prevention, Global Health Center; Dar es Salaam, Tanzania.
Andrea MbundaU.S. Centers for Disease Control and Prevention, Global Health Center; Dar es Salaam, Tanzania.
Jonathan M GrundU.S. Centers for Disease Control and Prevention, Global Health Center; Dar es Salaam, Tanzania.
Laura J McCormickU.S. Centers for Disease Control and Prevention, Global Health Center; Atlanta, GA, USA.
Terri HydeU.S. Centers for Disease Control and Prevention, Global Health Center; Atlanta, GA, USA.
Rebecca CaseyU.S. Centers for Disease Control and Prevention, Global Health Center; Atlanta, GA, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundCervical cancer is the fourth most common cancer among women globally, disproportionately affecting those in low- and middle-income countries (LMICs). In 2020, World Health Organization (WHO) Member States endorsed the 2030 Global Strategy toward Elimination of Cervical Cancer, recommending expanded access to human papillomavirus (HPV) vaccination. However, gaps remain in understanding how LMICs can sustain high HPV vaccine coverage. Tanzania, an early adopter among LMICs, introduced HPV vaccination into the national immunization schedule for 14-year-old girls in 2018 and achieved >90 % two-dose coverage by 2023. This study evaluated HPV vaccine program implementation in Tanzania, capturing stakeholder perspectives on barriers, facilitators, and recommendations.

methodsStakeholders were interviewed in April 2024 in a concurrent mixed-methods evaluation. Participants included national and subnational immunization staff (n = 18), and health workers, teachers, and community influencers (n = 80). Four of 31 regions were purposively selected based on criteria including first-dose HPV coverage (2020-2022) and urban/rural distribution. Two health facilities were randomly selected from a list of facilities in each region, along with two schools administering the vaccine from each facility's catchment area. Quantitative data were analyzed descriptively in STATA v.18, and qualitative data analyzed in ATLAS.ti Web (v19.3.1).

resultsPolitical support, quality improvement cycles, and integration with existing systems were identified as contributing to program success. Funding gaps and staff shortages-particularly in regions with low HPV vaccination coverage-were among the reported barriers, along with poor coordination between health and education sectors and low community awareness. Recommendations included increasing government funding, strengthening cross-sector collaboration, training stakeholders, and expanding dissemination channels to improve demand and address vaccine hesitancy.

conclusionsTanzania's experience offers lessons for HPV vaccination in similar contexts. Addressing key barriers through increased funding, improved coordination, and enhanced community engagement could improve HPV vaccination implementation in Tanzania and elsewhere, contributing to global cervical cancer elimination.

Indexed as

Immunization ProgramsPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsVaccinationAdolescentFemaleHumansStakeholder ParticipationTanzaniaVaccination CoveragePapillomavirus VaccinesBest practicesHuman papillomavirus vaccineLMICProgram evaluationSustainabilityTanzania

Identifiers

PMID40752248
PMCPMC12542858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.